Skip to main content

Table 1 Results of meta-analysis of expression of Bcl-2 and outcome in Breast Cancer.

From: Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

Endpoint and meta-analysis model Estimate of Relative Hazard Homogeneity Test
   (95% CI) p Q (df) p
Unadjusted Disease-Free Survival (8 studies, n = 2285)
   Fixed 1.5 (1.3–1.7) <0.001 22.4 (7) 0.002
   Random 1.7 (1.3–2.2) <0.001   
   Fixed * 1.7 (1.5–2.0) <0.001 6.6 (6) 0.360
   Random* 1.7 (1.5–2.1) <0.001   
Adjusted Disease-Free Survival (11 studies, n = 2128)
   Fixed 1.5 (1.3–1.7) <0.001 17.2 (10) 0.07
   Random 1.6 (1.3–2.0) <0.001   
Unadjusted Overall Survival (8 studies, n = 3910)
   Fixed 1.6 (1.4–1.7) <0.001 17.5 (7) 0.015
   Random 1.6 (1.4–2.0) <0.001   
   Fixed * 1.6 (1.5–1.8) <0.001 10.0 (6) 0.126
   Random* 1.7 (1.5–2.0) <0.001   
Adjusted Overall Survival (9 studies, n = 3624)
   Fixed 1.3 (1.2–1.4) <0.001 15.5 (8) 0.050
   Random 1.4 (1.2–1.6) <0.001   
  1. * values after exclusion of the study by Motolesse et al. [31] (n = 157)